Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

The Histone Deacetylase SIRT6 Restrains Transcription Elongation via Promoter-Proximal Pausing.

Etchegaray JP, Zhong L, Li C, Henriques T, Ablondi E, Nakadai T, Van Rechem C, Ferrer C, Ross KN, Choi JE, Samarakkody A, Ji F, Chang A, Sadreyev RI, Ramaswamy S, Nechaev S, Whetstine JR, Roeder RG, Adelman K, Goren A, Mostoslavsky R.

Mol Cell. 2019 Aug 22;75(4):683-699.e7. doi: 10.1016/j.molcel.2019.06.034. Epub 2019 Aug 6.

PMID:
31399344
2.

Loss of atrx cooperates with p53-deficiency to promote the development of sarcomas and other malignancies.

Oppel F, Tao T, Shi H, Ross KN, Zimmerman MW, He S, Tong G, Aster JC, Look AT.

PLoS Genet. 2019 Apr 10;15(4):e1008039. doi: 10.1371/journal.pgen.1008039. eCollection 2019 Apr.

3.

AKT1low Quiescent Cancer Cells Promote Solid Tumor Growth.

Alves CP, Dey-Guha I, Kabraji S, Yeh AC, Talele NP, Solé X, Chowdhury J, Mino-Kenudson M, Loda M, Sgroi D, Borresen-Dale AL, Russnes HG, Ross KN, Ramaswamy S.

Mol Cancer Ther. 2018 Jan;17(1):254-263. doi: 10.1158/1535-7163.MCT-16-0868. Epub 2017 Oct 20.

4.

Integrin β1 activation induces an anti-melanoma host response.

Ritsma L, Dey-Guha I, Talele N, Sole X, Salony, Chowdhury J, Ross KN, Ramaswamy S.

PLoS One. 2017 Apr 27;12(4):e0175300. doi: 10.1371/journal.pone.0175300. eCollection 2017.

5.

Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer.

Gallenne T, Ross KN, Visser NL, Salony, Desmet CJ, Wittner BS, Wessels LFA, Ramaswamy S, Peeper DS.

Oncotarget. 2017 Mar 15;8(13):20572-20587. doi: 10.18632/oncotarget.16244.

6.

SIRT6 Suppresses Pancreatic Cancer through Control of Lin28b.

Kugel S, Sebastián C, Fitamant J, Ross KN, Saha SK, Jain E, Gladden A, Arora KS, Kato Y, Rivera MN, Ramaswamy S, Sadreyev RI, Goren A, Deshpande V, Bardeesy N, Mostoslavsky R.

Cell. 2016 Jun 2;165(6):1401-1415. doi: 10.1016/j.cell.2016.04.033. Epub 2016 May 12.

7.

Light-controlled modulation of gene expression by chemical optoepigenetic probes.

Reis SA, Ghosh B, Hendricks JA, Szantai-Kis DM, Törk L, Ross KN, Lamb J, Read-Button W, Zheng B, Wang H, Salthouse C, Haggarty SJ, Mazitschek R.

Nat Chem Biol. 2016 May;12(5):317-23. doi: 10.1038/nchembio.2042. Epub 2016 Mar 14.

8.

High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines.

Yu C, Mannan AM, Yvone GM, Ross KN, Zhang YL, Marton MA, Taylor BR, Crenshaw A, Gould JZ, Tamayo P, Weir BA, Tsherniak A, Wong B, Garraway LA, Shamji AF, Palmer MA, Foley MA, Winckler W, Schreiber SL, Kung AL, Golub TR.

Nat Biotechnol. 2016 Apr;34(4):419-23. doi: 10.1038/nbt.3460. Epub 2016 Feb 29.

9.

AKT Inhibition Promotes Nonautonomous Cancer Cell Survival.

Salony, Solé X, Alves CP, Dey-Guha I, Ritsma L, Boukhali M, Lee JH, Chowdhury J, Ross KN, Haas W, Vasudevan S, Ramaswamy S.

Mol Cancer Ther. 2016 Jan;15(1):142-53. doi: 10.1158/1535-7163.MCT-15-0414. Epub 2015 Dec 4.

10.

Corrigendum: Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.

Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS, Gurumurthy S, Akbay EA, Sia D, Cornella H, Miltiadous O, Walesky C, Deshpande V, Zhu AX, Hezel AF, Yen KE, Straley KS, Travins J, Popovici-Muller J, Gliser C, Ferrone CR, Apte U, Llovet JM, Wong KK, Ramaswamy S, Bardeesy N.

Nature. 2015 Dec 3;528(7580):152. doi: 10.1038/nature16136. Epub 2015 Nov 18. No abstract available.

PMID:
26580013
11.

Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism.

Perera RM, Stoykova S, Nicolay BN, Ross KN, Fitamant J, Boukhali M, Lengrand J, Deshpande V, Selig MK, Ferrone CR, Settleman J, Stephanopoulos G, Dyson NJ, Zoncu R, Ramaswamy S, Haas W, Bardeesy N.

Nature. 2015 Aug 20;524(7565):361-5. doi: 10.1038/nature14587. Epub 2015 Jul 13.

12.

The histone deacetylase SIRT6 controls embryonic stem cell fate via TET-mediated production of 5-hydroxymethylcytosine.

Etchegaray JP, Chavez L, Huang Y, Ross KN, Choi J, Martinez-Pastor B, Walsh RM, Sommer CA, Lienhard M, Gladden A, Kugel S, Silberman DM, Ramaswamy S, Mostoslavsky G, Hochedlinger K, Goren A, Rao A, Mostoslavsky R.

Nat Cell Biol. 2015 May;17(5):545-57. doi: 10.1038/ncb3147. Epub 2015 Apr 27.

13.

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.

Niederst MJ, Sequist LV, Poirier JT, Mermel CH, Lockerman EL, Garcia AR, Katayama R, Costa C, Ross KN, Moran T, Howe E, Fulton LE, Mulvey HE, Bernardo LA, Mohamoud F, Miyoshi N, VanderLaan PA, Costa DB, Jänne PA, Borger DR, Ramaswamy S, Shioda T, Iafrate AJ, Getz G, Rudin CM, Mino-Kenudson M, Engelman JA.

Nat Commun. 2015 Mar 11;6:6377. doi: 10.1038/ncomms7377.

14.

Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.

Moore NF, Azarova AM, Bhatnagar N, Ross KN, Drake LE, Frumm S, Liu QS, Christie AL, Sanda T, Chesler L, Kung AL, Gray NS, Stegmaier K, George RE.

Oncotarget. 2014 Sep 30;5(18):8737-49.

15.

Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.

Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS, Gurumurthy S, Akbay EA, Sia D, Cornella H, Miltiadous O, Walesky C, Deshpande V, Zhu AX, Hezel AF, Yen KE, Straley KS, Travins J, Popovici-Muller J, Gliser C, Ferrone CR, Apte U, Llovet JM, Wong KK, Ramaswamy S, Bardeesy N.

Nature. 2014 Sep 4;513(7516):110-4. doi: 10.1038/nature13441. Epub 2014 Jul 2. Erratum in: Nature. 2015 Dec 3;528(7580):152.

16.

Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation.

Frumm SM, Fan ZP, Ross KN, Duvall JR, Gupta S, VerPlank L, Suh BC, Holson E, Wagner FF, Smith WB, Paranal RM, Bassil CF, Qi J, Roti G, Kung AL, Bradner JE, Tolliday N, Stegmaier K.

Chem Biol. 2013 May 23;20(5):713-25. doi: 10.1016/j.chembiol.2013.03.020.

17.

SYK regulates mTOR signaling in AML.

Carnevale J, Ross L, Puissant A, Banerji V, Stone RM, DeAngelo DJ, Ross KN, Stegmaier K.

Leukemia. 2013 Nov;27(11):2118-28. doi: 10.1038/leu.2013.89. Epub 2013 Mar 28.

18.

Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer.

Roti G, Carlton A, Ross KN, Markstein M, Pajcini K, Su AH, Perrimon N, Pear WS, Kung AL, Blacklow SC, Aster JC, Stegmaier K.

Cancer Cell. 2013 Mar 18;23(3):390-405. doi: 10.1016/j.ccr.2013.01.015. Epub 2013 Feb 21.

19.

The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia.

Banerji V, Frumm SM, Ross KN, Li LS, Schinzel AC, Hahn CK, Kakoza RM, Chow KT, Ross L, Alexe G, Tolliday N, Inguilizian H, Galinsky I, Stone RM, DeAngelo DJ, Roti G, Aster JC, Hahn WC, Kung AL, Stegmaier K.

J Clin Invest. 2012 Mar;122(3):935-47. doi: 10.1172/JCI46465. Epub 2012 Feb 13.

20.

HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans.

Marubayashi S, Koppikar P, Taldone T, Abdel-Wahab O, West N, Bhagwat N, Caldas-Lopes E, Ross KN, Gönen M, Gozman A, Ahn JH, Rodina A, Ouerfelli O, Yang G, Hedvat C, Bradner JE, Chiosis G, Levine RL.

J Clin Invest. 2010 Oct;120(10):3578-93. doi: 10.1172/JCI42442. Epub 2010 Sep 13.

21.

Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors.

Aste-Amézaga M, Zhang N, Lineberger JE, Arnold BA, Toner TJ, Gu M, Huang L, Vitelli S, Vo KT, Haytko P, Zhao JZ, Baleydier F, L'Heureux S, Wang H, Gordon WR, Thoryk E, Andrawes MB, Tiyanont K, Stegmaier K, Roti G, Ross KN, Franlin LL, Wang H, Wang F, Chastain M, Bett AJ, Audoly LP, Aster JC, Blacklow SC, Huber HE.

PLoS One. 2010 Feb 8;5(2):e9094. doi: 10.1371/journal.pone.0009094.

22.

Proteomic and genetic approaches identify Syk as an AML target.

Hahn CK, Berchuck JE, Ross KN, Kakoza RM, Clauser K, Schinzel AC, Ross L, Galinsky I, Davis TN, Silver SJ, Root DE, Stone RM, DeAngelo DJ, Carroll M, Hahn WC, Carr SA, Golub TR, Kung AL, Stegmaier K.

Cancer Cell. 2009 Oct 6;16(4):281-94. doi: 10.1016/j.ccr.2009.08.018.

23.

Identification of AML1-ETO modulators by chemical genomics.

Corsello SM, Roti G, Ross KN, Chow KT, Galinsky I, DeAngelo DJ, Stone RM, Kung AL, Golub TR, Stegmaier K.

Blood. 2009 Jun 11;113(24):6193-205. doi: 10.1182/blood-2008-07-166090. Epub 2009 Apr 17.

24.

Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation.

Hahn CK, Ross KN, Warrington IM, Mazitschek R, Kanegai CM, Wright RD, Kung AL, Golub TR, Stegmaier K.

Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9751-6. doi: 10.1073/pnas.0710413105. Epub 2008 Jul 7.

25.

Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.

Stegmaier K, Wong JS, Ross KN, Chow KT, Peck D, Wright RD, Lessnick SL, Kung AL, Golub TR.

PLoS Med. 2007 Apr;4(4):e122.

26.

Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators.

Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A, Nieto M, Du J, Stegmaier K, Raj SM, Maloney KN, Clardy J, Hahn WC, Chiosis G, Golub TR.

Cancer Cell. 2006 Oct;10(4):321-30. Epub 2006 Sep 28.

27.

The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease.

Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR.

Science. 2006 Sep 29;313(5795):1929-35.

29.

A method for high-throughput gene expression signature analysis.

Peck D, Crawford ED, Ross KN, Stegmaier K, Golub TR, Lamb J.

Genome Biol. 2006;7(7):R61.

30.

A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas.

Dahia PL, Ross KN, Wright ME, Hayashida CY, Santagata S, Barontini M, Kung AL, Sanso G, Powers JF, Tischler AS, Hodin R, Heitritter S, Moore F, Dluhy R, Sosa JA, Ocal IT, Benn DE, Marsh DJ, Robinson BG, Schneider K, Garber J, Arum SM, Korbonits M, Grossman A, Pigny P, Toledo SP, Nosé V, Li C, Stiles CD.

PLoS Genet. 2005 Jul;1(1):72-80. Epub 2005 Jul 25.

31.

Gefitinib induces myeloid differentiation of acute myeloid leukemia.

Stegmaier K, Corsello SM, Ross KN, Wong JS, Deangelo DJ, Golub TR.

Blood. 2005 Oct 15;106(8):2841-8. Epub 2005 Jul 5.

32.

Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation.

Stegmaier K, Ross KN, Colavito SA, O'Malley S, Stockwell BR, Golub TR.

Nat Genet. 2004 Mar;36(3):257-63. Epub 2004 Feb 8. Erratum in: Nat Genet. 2004 Apr;36(4):427. Nat Genet. 2005 Mar;37(3):328.

PMID:
14770183
33.

A molecular signature of metastasis in primary solid tumors.

Ramaswamy S, Ross KN, Lander ES, Golub TR.

Nat Genet. 2003 Jan;33(1):49-54. Epub 2002 Dec 9.

PMID:
12469122
34.

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning.

Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, Gaasenbeek M, Angelo M, Reich M, Pinkus GS, Ray TS, Koval MA, Last KW, Norton A, Lister TA, Mesirov J, Neuberg DS, Lander ES, Aster JC, Golub TR.

Nat Med. 2002 Jan;8(1):68-74.

PMID:
11786909
35.

How dangerous is that visit to the beach? A pilot study of beach injuries.

Grenfell RD, Ross KN.

Aust Fam Physician. 1992 Aug;21(8):1145-8.

PMID:
1530494
36.

Evaluation of environmental uranium contamination at the feed materials production center.

DODD AO, ROSS KN.

HASL Rep. 1959 Sep;58:175-9. No abstract available.

PMID:
13817127

Supplemental Content

Support Center